Tissa Hata, MD
Enriched profileHS Clinical Professor of Dermatology; Dermatology Clinical Service Chief; Director, UCSD Dermatology Clinical Trials Unit · University of California, San Diego (UCSD)
Tissa Hata is HS Clinical Professor of Dermatology; Dermatology Clinical Service Chief; Director, UCSD Dermatology Clinical Trials Unit at University of California, San Diego (UCSD). OpenAlex indexes 114 publications with 7,869 citations (h-index 42); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Dermatology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Tissa Hata, MD, is HS Clinical Professor of Dermatology at University of California, San Diego (UCSD), Department of Dermatology. The public record shows 114 publications with 7,869 citations (h-index 42), centered on Atopic Dermatitis / Eczema. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 9 companies, 2 NIH-funded awards (2014–2018).
- Most recent indexed publication: 2024 · The Journal of experimental medicine
- Top research focus: Atopic Dermatitis / Eczema
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Targeted Investigation of Microbiome Elimination
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
Sponsor: University of California, San Diego
Industry payments
Updated 27 Aug 2026
9 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year20251 payment
- Galderma Laboratories, L.P.Program year20251 payment
- Incyte CorporationProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
40%Azole Antifungal29.6%Ketoconazole100%Part D≥110 patientsLincosamide Antibacterial5.1%Clindamycin Phosphate100%Part D≥21 patientsDermatology
16.2%Corticosteroid9.5%Triamcinolone Acetonide83%Fluocinolone Acetonide17%Part D<11 patientsOther antifungals for topical use3.6%Ciclopirox100%Part D≥18 patientsCancer & immunology
13.2%Nucleoside Metabolic Inhibitor5.9%Fluorouracil100%Part D≥41 patientsRetinoid2.3%Tretinoin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
2 NIH research awards on record, funded 2014–2018 per NIH RePORTER. The latest:
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- CXCL12+ dermal fibroblasts promote neutrophil recruitment and host defense by recognition of IL-17.
The Journal of experimental medicine
Article2024
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/tissa-hata-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
dermrefoundation.org/hata.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dermrefoundation.org ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
- Dermatology residency
Harvard Medical School (Chief Resident); residency and fellowship, UCLA School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗ - Board certified
American Board of Dermatology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dermrefoundation.org ↗
Editorial & leadership roles
journal and society appointments- Dermatology Clinical Service Chief
UC San Diego Health
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dermatology.ucsd.edu ↗ - Director
UCSD Dermatology Clinical Trials Unit (Adult/Clinical and Translational Trials Unit)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dermrefoundation.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan